As such, by harnessing the complexity of the Eph/ephrin system, inhibition of ephrin-B2 would in itself be an effective ‘combinatorial therapy’, capable of suppressing two critical GSC-intrinsic properties, namely perivascular invasion and proliferation, and might thus represent an attractive strategy for blocking GBM progression and recurrence. Here, EFNB2 is linked to glioblastoma.